<DOC>
	<DOCNO>NCT00984152</DOCNO>
	<brief_summary>Raltegravir unique mechanism action , may also unique effect suppression viral replication , viral reservoir , immune reconstitution blood important compartment . This may part due pharmacokinetics Raltegravir blood gut tissue . Efavirenz comparator antiretroviral drug study , drug use part three-drug regimen tenofovir emtricitabine . The primary objective determine difference effect 2 anti-retroviral regimen , Raltegravir + Truvada versus Atripla , respect : 1 . Viral load plasma , genital tract ( vaginal secretion ) , gut ( situ hybridization ) . 2 . Latent viral reservoir ( pro-viral DNA ) peripheral blood genital tract . 3 . Immune effect ( CD4/CD8 immunophenotypes ) gut PBMCs plasma cytokine profile . The secondary objective determine pharmacokinetics Raltegravir blood gut tissue ; relative tissue/compartment penetration compare Efavirenz .</brief_summary>
	<brief_title>Trial TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz HIV-1-Infected Women</brief_title>
	<detailed_description>This phase III , prospective , randomize ( 1:1 ) , multicenter , open label study compare effect two HAART regimen : - Arm A : Raltegravir 400 mg PO BID + TDF/FTC ( Truvada , 300/200 mg ) One PO Daily - Arm B : Efavirenz + TDF/FTC ( Atripla ) Once PO Daily The following local site : Mt . Sinai , Rush University Medical Center , Stroger Hospital , University Chicago University Illinois work together enroll 10 eligible woman meet eligibility criterion ( 5 per study arm ) one year time period . These 10 woman randomize 1:1 receive either TDF/FTC + Raltegravir TDF/FTC + Efavirenz ( Atripla ) . There 2 baseline evaluation prior initiation study therapy . Subjects follow 48 week initiation study treatment .</detailed_description>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . Eligible subject antiretroviral naïve ( &lt; 7 day HAART time prior entry ) plasma HIV1 RNA &gt; 50,000 copies/mL ( obtain within 90 day prior study entry laboratory CLIA certification equivalent ) moderate immune suppression within 90 day prior study entry . 2 . HIV1 infect , document licensed ELISA test kit confirm Western blot time prior study entry . HIV1 culture , HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA acceptable alternative confirmatory test . Alternatively , license ELISA available , two HIV1 RNA value &gt; 2000 copies/mL least 24 hour apart perform laboratory CLIA certification equivalent may use document infection . 3 . Female sex , Age &gt; 18 &lt; 60 year , Premenopausal . 4 . Screening CD4+ Tcell count 200350 cells/mm3 obtain within 90 day prior study entry laboratory CLIA certification equivalent . 5 . The absence exclusionary resistance mutation genotypic resistance assay ( absence exclusionary NRTI NNRTI resistance mutation genotype test ) 6 . Antiretroviral ( ARV ) drugnaïve ( defined 7 day ARV treatment time prior entry ) . 7 . Laboratory value obtain within 45 day prior study entry : Absolute neutrophil count ( ANC ) 500/mm3 Hemoglobin 8.0 g/dL Platelet count 40,000/mm3 AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase 5 ULN Total bilirubin 2.5 x ULN Calculated creatinine clearance ≥60 mL/min estimate CockcroftGault equation : For woman , multiply result 0.85 = CrCl ( mL/min ) 8 . Negative serum urine pregnancy test within 48 hour prior initiate study medication unless otherwise specify product labeling . Female candidate reproductive potential defined woman regular menses precede 24 month 9 . Contraception requirement woman undergone surgical sterilization ( e.g. , hysterectomy , bilateral oophorectomy , bilateral tubal ligation ) . 10 . Female candidate reproductive potential , participate sexual activity could lead pregnancy , must agree following : If regimen include EFV , must agree use least one reliable method contraception receive protocolspecified drug 6 week stop medication . If regimen include EFV , must agree use two reliable method contraception : barrier method contraception ( e.g. , condom , diaphragm , cervical cap without spermicide ) together another reliable form contraceptive ( e.g. , second barrier method , IUD , hormonebased contraceptive ) receive EFV 6 week stop EFV . 1 . Menopausal ( may affect quantity genital tract secretion ) serious illness require treatment and/or hospitalization patient complete therapy 2 . Any active infection , include coinfection hepatitis B C 3 . Any neoplasm 4 . Immunosuppressive therapy 5 . Requirement medication prohibit study treatment 6 . Significant liver renal dysfunction 7 . Baseline resistance study drug genotypic test NRTI : M41L , K65 R , D76N , T69D , K70R , L74V/I , y115F , Q151M , M184V , L210W , T215any , K219Q/E NNRTI : L100I , K103N , V106A/M , V108I , Y181C/I , Y188C/L/H , G190anyA/S 8 . Alcohol substance abuse problem psychiatric condition impair ability subject comply study protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Women</keyword>
	<keyword>Viral Suppression</keyword>
	<keyword>Viral Reservoir</keyword>
	<keyword>Immune Parameters</keyword>
	<keyword>Gut</keyword>
	<keyword>Genital Tract</keyword>
</DOC>